Physician profile
Stephen Daniel Conrad
NPI 1346735370
$5,623.98
in general payments reported to CMS, 2019-2025
32 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $920 · 2023: $816 · 2024: $1,212 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.45 |
| Education | $262.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,721.43 | 2021-2025 | |
| Lilly USA, LLC | $481.85 | 2021-2023 | Mounjaro, Reyvow, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.78 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $297.37 | 2021-2025 | |
| Novo Nordisk INC | $282.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.81 | 2021-2025 | Airsupra |
| Vanda Pharmaceuticals INC. | $255.84 | 2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $221.14 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $220.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $156.60 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $143.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $124.08 | 2021-2025 | Bexsero, Rotarix, Pediarix |
| Corcept Therapeutics | $121.19 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $97.43 | 2021-2022 | |
| Astellas Pharma US INC | $93.35 | 2021-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.79 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.69 | 2021 | |
| Alkermes, INC. | $81.07 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Avanir Pharmaceuticals, INC. | $75.78 | 2022 | |
| Corium, LLC | $73.33 | 2022-2023 | Azstarys |
| Amgen INC. | $61.94 | 2022-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $59.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.34 | 2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $49.34 | 2025 | Qelbree |
| Lundbeck LLC | $39.54 | 2023-2025 | Rexulti |
| Dexcom, INC. | $35.88 | 2024-2025 | Dexcom G6 Transmitter |
| Organon LLC | $30.65 | 2022-2023 | Nexplanon |
| Sanofi Pasteur INC. | $24.95 | 2025 | |
| Neurocrine Biosciences, INC. | $21.39 | 2022 | |
| Noven Therapeutics, LLC | $19.81 | 2025 | Xelstrym, Secuado |
| Tonix Medicines, INC. | $16.51 | 2025 | Tonmya |
| Eisai INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.